9月25日，南模生物涨0.57%，成交额5400.51万元。两融数据显示，当日南模生物获融资买入额425.21 万元，融资偿还579.84万元，融资净买入-154.63万元。截至9月25日，南模生物融资融券余额合计1.05 亿元。 融资方面，南模生物当日融资买入425.21万元。当前融资余额1.05亿元，占流通市值的2.56%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，南模生物9月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，上海南方模式生物科技股份有限公司位于上海市浦东新区琥珀路63弄1号6层，成立日期2000 年9月20日，上市日期2021年12月28日，公司主营业务涉及从事基因修饰动物模型的研发、生产、销售 及相关技术服务。主营业务收入构成为：标准化模型48.34%，模型技术服务21.92%，模型繁育 19.50%，定制化模型9.34%，其他(补充)0.91%。 机构持仓方面，截止2025年6月30日，南模生物十大流通股东中，融通健康产业灵活配置混合A/B （0 ...

Core Viewpoint - Nanmo Biotechnology experienced an 8.34% increase in stock price on August 27, with a trading volume of 250 million yuan, indicating strong market interest and activity [1]. Financing Summary - On August 27, Nanmo Biotechnology had a financing buy-in amount of 24.30 million yuan, with a financing repayment of 27.23 million yuan, resulting in a net financing buy of -2.93 million yuan [1]. - As of August 27, the total financing and securities lending balance for Nanmo Biotechnology was 110 million yuan, which represents 2.28% of its circulating market value, indicating a high level of financing activity compared to the past year [1]. - The company had no shares sold or repaid in securities lending on August 27, with a securities lending balance of 0.00 yuan, also reflecting a high level compared to the past year [1]. Business Performance - As of March 31, the number of shareholders for Nanmo Biotechnology was 6,252, an increase of 1.72% from the previous period, while the average circulating shares per person decreased by 1.70% to 7,899 shares [2]. - For the first quarter of 2025, Nanmo Biotechnology reported a revenue of 88.40 million yuan, representing a year-on-year growth of 6.59%, while the net profit attributable to the parent company was -0.97 million yuan, showing a significant year-on-year increase of 92.50% [2]. Dividend and Shareholding Structure - Since its A-share listing, Nanmo Biotechnology has distributed a total of 30.04 million yuan in dividends, with 10.00 million yuan distributed over the past three years [3]. - As of March 31, 2025, among the top ten circulating shareholders, the "Rongtong Health Industry Flexible Allocation Mixed A/B" fund held 950,000 shares, a decrease of 200,000 shares from the previous period, while "Zhaoshang Quantitative Selected Stocks Initiated A" and "Jiaoyin Medical Innovation Stocks A" were newly added shareholders with holdings of 384,300 shares and 374,900 shares, respectively [3].

Core Insights - The integration of artificial intelligence (AI) into business operations is accelerating, evolving from an auxiliary tool to a new type of "productivity system" in the context of a restructured global trade landscape and a stable Chinese economy [2] - The "2025 New Beijing News Beike Finance Annual Conference" highlighted the theme "China's Economy: Open and Resilient Co-Growth," where the "China Entrepreneur AI Application Research Report (2025)" was released, revealing ten trends in AI application among Chinese enterprises [2] Group 1: AI Deployment Status - Nearly 90% of enterprises have implemented AI in some capacity, indicating a shift from optional use to a systematic variable that enhances efficiency and drives organizational change [6][29] - 65.63% of enterprises have established or are planning to set up AI-related organizational structures, focusing on decision-making, research and development, and customer service [8][29] - The preferred methods for AI deployment include public APIs (41.41%), customized models (34.38%), and embedded tools (30.47%), with a focus on content generation, customer insights, and internal automation [10] Group 2: AI Transformation and Governance - 65.63% of enterprises have established or plan to create AI-related positions, with the majority integrating these roles into data/IT departments, marking a transition from project-based to organizational AI development [12] - 11.72% of enterprises have established AI governance systems, while 51.57% have partial regulations or governance plans, indicating a nascent stage of governance development [17] - 78.13% of enterprises anticipate that AI will optimize or significantly transform industry structures within three years, highlighting the perceived strategic importance of AI [20][24] Group 3: Expectations and Support Needs - 68.75% of enterprises expect AI to yield significant benefits in cost reduction and efficiency improvement, with positive expectations also noted in user experience and competitive differentiation [22] - There is a strong demand for supportive policies, with 62.5% of enterprises calling for AI talent training, 60.16% seeking subsidies for small and medium-sized enterprises, and 51.56% focusing on data compliance [26] - The report emphasizes that AI has become a critical lever for enhancing efficiency, resilience, and competitiveness, while also noting challenges related to organizational capability, governance, and transformation pathways [29]